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Abstract
Background: The goal of the present study was to explore the differences in effects between erythropoiesis-
stimulating agent (ESA) types on hemoglobin (Hb) level at the initiation of maintenance dialysis.
Methods: This was a cross-sectional study. From January 2006 to October 2012, 2920 patients with end-stage
kidney disease commenced hemodialysis (HD) at nine participating hospitals. The criteria for exclusion from the
database were (1) presence of cancer or gastrointestinal bleeding and (2) serum C-reactive protein ≥0.3 mg/dL. A
total of 1263 patients were entered into the final database. We explored the association of yearly trend of Hb level
just before the first HD session with the different types of ESA in the predialysis period.
Results: During the 7-year study period, patients’ Hb levels at the initiation of dialysis dramatically increased from
8.6 to 9.1 g/dL. Parallel to this increase, the use of long-acting ESA also increased from 0 to 80 %. A higher level of
Hb was confirmed in the long-acting ESA group compared with the short-acting group (9.5 vs. 8.7 g/dL, P < 0.01).
Multivariate regression analysis showed a strong association of Hb level with the use of long-acting ESA (r = 0.155,
P = 0.003), even after adjusting for confounding variables and estimated dose of epoetin.
Conclusions: The change in the type of ESA used from short-acting to long-acting played a role in the increase of
patients’ Hb levels at the initiation of dialysis. A long-acting ESA has the potential effect of maintaining an optimal
Hb level even in the advanced stages of CKD.
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Background
Anemia plays a crucial role in the promotion of cardiac
remodeling and, consequently, in the onset of cardiac
events in patients with chronic kidney disease (CKD) [1, 2].
This is the reason why vigorous debate continues in the
search for an optimal target hemoglobin (Hb) level,
achieved by treatment with an erythropoiesis-stimulating
agent (ESA) for preventing cardiac abnormalities and
events in the predialytic phase of CKD [3]. Unfortunately,
even among CKD patients who receive ESA therapy, a
higher percentage of anemia, with Hb levels <11 g/dL, is
observed in patients in the more advanced stages of CKD
[4]. Indeed, previous data from our multicenter study of
Japanese dialysis patients clearly revealed that the mean
Hb level at the initiation of dialysis was 8.5 g/dL [5], which
is lower than the target level recommended by current
international guidelines [6–8]. It is also known that the on-
set of cardiac events such as congestive heart failure and
myocardial ischemia increase close to the time of initiation
of dialysis [9, 10]. Although the evidence is still limited, we
are assuming that this progression of anemia plays, at least
in part, a role in the occurrence of cardiac events in the ad-
vanced stages of CKD. The occurrence of cardiac remodel-
ing and events may decrease or become less severe if the
Hb level could be kept at an optimum level—that is, over
10 g/dL—even at the initiation of dialysis.
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changing to the long-acting type, such as darbepoetin and
continuous erythropoietin receptor activators (CERA),
rather than epoetin-α and -β. Referring to the dose con-
version ratio from darbepoetin to epoetin [11], a higher
prescribing dose of epoetin in the predialytic phase of
CKD is theoretically more feasible than before. However,
the evidence is still limited about the effect of long-acting
ESAs on anemia in the advanced stages of CKD. The use
of long-acting ESAs could increase the Hb level in the
advanced stages of CKD. The goal of the present study
was to explore the association of the yearly trend of mean
Hb level with the change in the type of ESA used at the
initiation of renal replacement therapy (RRT) during
2006–2012. Our hypothesis is that Hb level at the initi-
ation of dialysis has increased after the introduction of the
long-acting ESAs into the clinical practice compared with
before their approval of clinical use.Methods
Study design and patients
We conducted a retrospective study for cross-sectional
comparative analysis of patients with ESKD among dif-
ferent eras by using the database of the Japanese Study
Group for Assessing Initiation of Renal Replacement
Therapy (J-START), which includes the nephrology units
of nine teaching hospitals in Japan. The objective of J-
START is to create a shared database on end-stage kid-
ney disease (ESKD) patients at the time of starting RRT
for the conduct of clinical research. From January 2006
to October 2012, there were 2920 ESKD patients who
commenced chronic hemodialysis (HD) at the nine hos-
pitals. Clinical information on those patients was added
to the J-START database. In order to explore the precise
effect of ESAs on anemia, the ESKD patients with major
etiological factors for low responsiveness to ESA [8]
were excluded. The following exclusion criteria were
employed: (1) gastrointestinal bleeding or other bleeding
disease (n = 40), (2) cancer (n = 159), and (3) inflamma-
tion, with serum C-reactive protein (CRP) level >0.3 mg/
dL (n = 1458), such as in infectious disease or auto-
immune disease. As a result, 1263 ESKD patients were
available for inclusion in the database of this study. We
explored the association of the yearly trend of the Hb
levels just before patients’ first HD session with the
change of ESA type in the predialysis period. The clinical
factors associated with Hb level were also explored.
The ethics committee for clinical research of Toho
University Ohashi Medical Center approved the study
protocol [permission No. 13-52, 13-61]. This study ad-
hered to the Declaration of Helsinki. Informed consents
to participate in this study and for the publication were
obtained from all participants.Data collection
Using the study protocol, clinical information was re-
corded for all patients at each nephrology unit immedi-
ately prior to their first HD session. Information was
also collected on the use of oral medications and ESA
per month during the predialysis period. Blood pressure
(BP) was recorded in the supine position, and a blood
sample was collected just before the first HD session.
The comorbid conditions at the initiation of dialysis
were reviewed from the medical records. The Hb was
corrected by dose of ESA/1000 units. The estimated
glomerular filtration rate (eGFR) was calculated by using
the new Japanese equation [12]: eGFR (mL/min/
1.73 m2) = 194 × Cr−1.094 × age−0.287 (×0.739 for women).
Body mass index (BMI) at optimal weight was calculated
as the weight in kilograms divided by the square of the
height in meters. Patients with “vascular access” were
the patients for whom an arterio-venous fistula was sur-
gically created according to a planned schedule before
initiation of dialysis. Standard chest radiography pro-
ceeded on the day of the first HD session. The cardio-
thoracic ratio (CTR) was determined by dividing the
maximal horizontal width of the heart by the horizontal
inner width of the rib cage. Medications were classified as
ESA, angiotensin-converting enzyme inhibitors (ACE-I),
angiotensin-II receptor blockers (ARB), vitamin D, iron
agents, and AST-120. AST-120 is a carbonaceous ad-
sorbent that is used to treat CKD patients in Japan. It
has been reported that AST-120 removes uremic
toxins and reduces oxidative stress [13, 14]. The duration
of nephrologist care was defined as the length of follow-
up days by nephrologists prior to the initiation of HD.
ESA type
In Japan, epoetin-α and -β have been approved for
use during the predialytic phase of CKD since 1995.
Darbepoetin-α and methoxy polyethylene glycol-epoetin β
(Continuous Erythropoietin Receptor Activator; CERA)
were registered in 2010 and 2011 respectively, all for use
during the predialytic phase of CKD. Epoetin-α and -β are
short-acting ESAs, and darbepoetin-α and CERA are
long-acting ESAs. The dose conversion ratios from darbe-
poetin-α and CERA to epoetin α/β were used 1:200 [15]
and 1:270 [16] respectively.
Statistical analysis
Data are expressed as the mean ± SD, median [interquar-
tile range], or percentage. Subject characteristics were
compared across CKD stages using chi-square tests for
categorical variables, analysis of variance (ANOVA) for
normally distributed variables, and Kruskal-Wallis tests
for non-normally distributed variables. As appropriate, the
Jonckheere-Terpstra trend test was used for assessing the
yearly trend of Hb concentration. To assess the
Table 1 The characteristics of the study patients and temporal trends for 7 years
Total 2006 2007 2008 2009 2010 2011 2012 p value
Patients number 1263 195 162 210 184 188 189 135
Age, years 64.5 ± 14.0 60.2 ± 14.8 63.5 ± 12.9 63.5 ± 14.1 65.9 ± 14.1 64.8 ± 13.5 67.8 ± 13.3 66.6 ± 13.9 .000
Male, % 65 65 65 68 63 68 60 64 .722
Diabetes, % 46 50 48 43 51 44 42 45 .517
BMI, kg/m2 23.1 ± 4.7 22.6 ± 5.5 23.1 ± 3.9 22.7 ± 3.4 23.1 ± 4.5 23.7 ± 6.4 22.9 ± 4.6 23.8 ± 4.2 .212
Duration of nephrologist
care, days
625 552 432 608 566 697 796 775 .109
[174, 1557] [83, 1789] [175, 1450] [185, 1346] [138, 1356] [160, 1860] [206, 1530] [254, 1827]
Vascular access, % 70 68 70 70 69 68 68 77 .615
Primary disease, % .000
Diabetic nephropathy 44 47 48 42 47 43 40 40
Glomerulonephritis 21 31 17 25 15 18 18 23
Nephrosclerosis 16 7 17 10 19 19 25 22
PCK 4 2 5 4 3 5 5 2
Others 16 14 14 20 17 16 13 13
Systolic BP, mmHg 155 ± 25 152 ± 25 159 ± 24 154 ± 25 153 ± 26 155 ± 25 154 ± 23 156 ± 25 .222
Diastolic BP, mmHg 78 ± 14 77 ± 13 80 ± 14 79 ± 13 76 ± 14 79 ± 14 78 ± 14 81 ± 14 .067
CTR, % 53.3 ± 6.7 52.6 ± 6.5 53.9 ± 6.3 53.4 ± 6.9 53.7 ± 6.6 53.5 ± 6.4 52.9 ± 7.9 53.2 ± 6.2 .659
Hemoglobin, g/dL 8.7 ± 1.5 8.5 ± 1.6 8.6 ± 1.3 8.6 ± 1.6 8.7 ± 1.4 8.6 ± 1.5 9.0 ± 1.5 9.1 ± 1.4 .002
Hemoglobin/dose of ESAa 0.46 0.48 0.43 0.43 0.58 0.58 0.46 0.40 .050
[0.35, 0.72] [0.35, 0.71] [0.35, 0.70] [0.35, 0.69] [0.38, 0.77] [0.38, 0.73] [0.33, 0.76] [0.27, 0.73]
Albumin, g/dL 3.3 ± 0.5 3.3 ± 0.5 3.3 ± 0.5 3.4 ± 0.5 3.3 ± 0.5 3.3 ± 0.5 3.4 ± 0.5 3.4 ± 0.5 .153
Creatinine, mg/dL 9.4 ± 3.2 9.8 ± 3.8 9.7 ± 3.5 9.1 ± 2.9 9.4 ± 3.2 9.1 ± 3.1 9.3 ± 3.1 9.6 ± 3.0 .228
eGFR, mL/min/1.732 5.1 ± 2.2 5.2 ± 2.2 5.0 ± 1.9 5.4 ± 2.1 5.2 ± 2.9 5.3 ± 1.8 5.0 ± 1.9 4.8 ± 1.9 .280
Total cholesterol, mg/dL 172 ± 50 177 ± 53 180 ± 53 170 ± 47 170 ± 42 169 ± 56 171 ± 52 168 ± 44 .401
Triglyceride, mg/dL 111 113 110 106 114 103 126 109 .272
[81, 157] [80, 156] [79, 167] [79, 201] [81, 152] [76, 161] [88, 163] [83, 149]
HDL-C, mg/dL 48 ± 16 49 ± 18 50 ± 19 48 ± 15 46 ± 14 49 ± 17 49 ± 16 46 ± 15 .223
Calcium, mg/dL 7.8 ± 0.9 7.8 ± 1.0 7.8 ± 1.0 7.9 ± 0.9 7.8 ± 0.9 7.8 ± 0.9 8.0 ± 0.9 7.8 ± 0.9 .092
Phosphate, mg/dL 6.1 ± 1.6 6.1 ± 1.6 5.9 ± 1.5 5.9 ± 1.4 6.1 ± 1.7 6.1 ± 1.5 6.0 ± 1.6 6.4 ± 1.5 .045
Ca x P product 47 ± 13 47 ± 13 46 ± 13 46 ± 12 46 ± 14 47 ± 12 48 ± 14 49 ± 15 .260
i-PTH, pg/mL 271 210 264 300 285 272 266 331 .000
[169, 414] [141, 346] [179, 382] [170, 425] [185, 416] [171, 426] [159, 393] [188, 468]
CRP, mg/dL 0.10 0.10 0.10 0.10 0.08 0.10 0.10 0.13 .000
[0.04, 0.17] [0.04, 0.15] [0.0, 0.14] [0.0, 0.13] [0.02, 0.10] [0.02, 0.20] [0.05, 0.20] [0.05, 0.20]
Glucose, mg/dL 137 ± 52 142 ± 61 144 ± 61 135 ± 47 136 ± 53 137 ± 49 130 ± 47 139 ± 44 .243
Fe, μg/dL 67 ± 35 66 ± 36 64 ± 31 69 ± 33 68 ± 33 70 ± 37 66 ± 35 66 ± 39 .772
TIBC, μg/dL 233 ± 46 229 ± 46 239 ± 41 236 ± 51 229 ± 49 230 ± 48 231 ± 42 236 ± 43 .352
Ferritin, ng/dL 117 117 111 141 110 124 126 101 .309
[57, 209] [61, 199] [56, 194] [68, 232] [51, 114] [57, 225] [56, 213] [42, 187]
ESA, % 78 81 74 77 79 79 80 80 .810
long-acting ESA, % 15 0 0 0 0 2 49 80 .000
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Table 1 The characteristics of the study patients and temporal trends for 7 years (Continued)
ARB/ACE-I, % 64 56 67 69 61 70 65 61 .051
Vitamin D, % 31 26 34 271 23 36 32 41 .007
AST-120, % 19 17 18 27 19 19 16 14 0.054
Iron, % 19 31 18 20 18 14 23 19 .403
Data are expressed as the mean ± SD, median [interquartile range], or percentage
BMI body mass index, PCK polycystic kidney disease, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density
lipoprotein, i-PTH intact parathyroid hormone, CRP C-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin
receptor blocker, ACE-I angiotensin-converting enzyme inhibitor
aHemoglobin was corrected by dose of ESA per 1000units
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univariate regression analysis was employed. Dummy vari-
ables were used for gender (0 for female, 1 for male), pri-
mary renal disease (0 for non-diabetic nephropathy, 1 for
diabetic nephropathy), smoking history (0 for negative, 1
for positive), and each medication (0 for not used, 1 for
used). Dummy variables were also used for type of ESA (0
for short-acting ESA, 1 for long-acting ESA). The monthly
ESA dose was evaluated as a numerical factor. The dose
was also divided by 1000 units for analysis as appropriate.
Multivariate regression analysis was also performed to
identify independent determinants of Hb concentration.
In all analyses, a probability (P) value <0.05 was consid-
ered statistically significant. All statistical analyses were




The mean age of the entire group of study subjects was
64.5 ± 14.0 years. The percentage of men (64.6 %) and the
percentage of patients with diabetic nephropathy (43.8 %)
were similar to the percentages previously reported at the
initiation of dialysis for the entire Japanese dialysis popula-
tion [17]. The mean serum creatinine (Cr) and eGFR at the
initiation of renal replacement therapy (RRT) were 9.5 ±
3.3 mg/dL and 5.2 ± 2.2 mL/min/1.73 m2, respectively,
which were similar to the levels for the Japanese dialysis
population [17]. Therefore, our subjects seemed to consti-
tute a suitable sample of Japanese dialysis patients. The
mean Hb level was 8.8 ± 1.5 g/dL, and the median monthly
estimated dose of epoetin just before the initiation of HD
was 12,000 units per month. Other clinical characteristics
are shown in the first column of Table 1.
Yearly trend of patient characteristics
We examined changes in the clinical features of the
study patients during the study period (2006–2012). Age
increased over time from 60 to 67 years (P < 0.001 for
trend). The Hb level dramatically increased over time
(P < 0.001 for trend) from 8.6 to 9.1 g/dL. In particu-
lar, as shown in Fig. 1, the rise in the Hb level was
confirmed during 2011 and 2012, along with a significantand parallel increase in the proportion of usage of long-
acting ESAs (Fig. 2). The concentrations of iron, total
iron-binding capacity (TIBC), and ferritin did not show
any significant changes during the 7-year study period.
The ratio of iron medicine users increased during the last
2 years, in 2011 and 2012.
Differences in Hb level and clinical characteristics between
ESA types
The comparison of the Hb level between the three pa-
tient groups (long-acting ESA users, short-acting ESA
users, and non-ESA users) is shown in Fig. 3. The Hb
level of the patients in the long-acting ESA group was
significantly higher than the Hb levels of the short-
acting ESA group and the non-ESA group. No signifi-
cant difference was observed between the non-ESA users
and the short-acting ESA users. The other clinical char-
acteristics in three patient groups are shown in Table 2.
Some tendencies between three patient groups are seen
in the Table. Older, longer duration of nephrologist care,
higher albumin level, lower eGFR, and higher usage of
vitamin D were found in ESKD patients with long-acting
ESA compared with those of the other two groups.
Univariate regression analysis determined the factors
associated with Hb
Among the clinical characteristics, planned vascular ac-
cess, serum albumin, eGFR, total cholesterol, Ca, TIBC,
long-acting ESA use, and estimated long-acting ESA
dose were significantly correlated with Hb level, as shown
in Table 3. Significant negative associations were observed
between Hb and CTR and serum phosphate level.
Independent association of long-acting ESA with Hb
Table 4 presents the independent association of long-
acting ESA use and its estimated dose with Hb. Dummy
variables were used for type of ESA (0 for short-acting
ESA, 1 for long-acting ESA). The positive association of
long-acting ESA use with Hb remained significant after
adjustment for age, gender, diabetes, BMI, systolic BP,
vascular access, duration of nephrologist care, CTR, and
estimated long-acting ESA dose as shown in model 2.



















Fig. 1 The concentration of Hb dramatically increased over time
(P < 0.001 for trend) from 8.6 to 9.1 g/dL in the 7-year study period.
The remarkable increase in Hb level was confirmed between 2010 and
2011, along with a significant and parallel increase in the proportion of
























Fig. 3 The Hb level of patients who received long-acting ESA was
significantly higher than in the patients who received no ESA (P< 0.001)
or short-acting ESA (P < 0.001). There was no significant difference in Hb
levels between the non-ESA and short-acting ESA patient groups
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markers of lipid and glucose metabolism (total choles-
terol, triglycerides, high-density lipoprotein (HDL)-C,
and glucose), markers of calcium phosphate metabolism
(calcium, phosphate, intact parathyroid hormone, use of
vitamin D), markers for iron metabolism (Fe, TIBC, fer-
ritin, use of iron agent), and medications (use of ACE-I/
ARB, AST-120) as shown in models 3 through 7. Finally,
as shown in model 8, the independent association of
long-acting ESA with Hb was confirmed by multiple lin-
ear regression analysis, including all markers of models20 26 23 21 21 21 20
0 0 0 0 2
49
80















Fig. 2 The grouped bar graph depicts the yearly trend of the proportion
of ESA. The use of long-acting ESA (gray bar) significantly increased in
last 2 years of the study, 2011 and 2012 (P< 0.001 for trend). About
20 % of the patients did not use ESA (black bar) in any calendar year.
White bar means percentage of patients with short-acting ESA2 to 7. On the other hand, no significant associations of
Hb level with estimated long-acting ESA dose were ob-
served in all models of multiple linear regression analysis
including long-acting ESA use.
Association of long-acting ESA with categorical Hb levels
For real world clinical implication, multiple logistic
regression analysis was performed to identify the associ-
ation of long-acting ESA with categorical Hb levels by
using dummy variables, 0 for short-acting ESA, 1 for
long-acting ESA. As shown in Table 5, higher level of
categorical Hb level was more associated with the use of
long-acting ESA compared with reference category of
Hb 8.0–8.9 after adjusted by age, sex, BMI, diabetes, al-
bumin, eGFR, and CRP. No significant associations were
observed between categorical Hb level less than 8.0 and
use of long-acting ESA.
Discussion
Main findings of current study
Based on the registry data of Japanese dialysis patients
from nine hospitals, the mean Hb level at the initiation
of dialysis is 8.5 g/dL, which is much lower than the op-
timal Hb level recommended by international guidelines
[6–8]. It remains unclear whether the change of ESA
type has exerted an advantageous effect on the Hb level
at the initiation of maintenance dialysis. Our present
multicenter study clearly showed three important find-
ings: (1) Hb level at the initiation of dialysis has dramat-
ically increased in the past 2 years (2011 and 2012)
compared with the Hb levels from 2006 to 2010; (2) par-
allel with this trend, the main type of ESA used has dras-
tically changed from short-acting such as epoetin α/β to
long-acting such as darbepoetin-α and CERA between
2010 and 2011; and (3) the use of long-acting ESA was
strongly and independently associated with Hb level in
our study subjects. These findings suggest that long-
Table 2 The characteristics of 3 patient groups, non-ESA, ESA-short, and ESA-long
Non-ESA Short-acting ESA Long-acting ESA p value
Patients number 271 788 204
Age, years 63.8 ± 14.9 64.2 ± 13.7 67.0 ± 13.9 .021
Male, % 66 65 61 .546
Diabetes, % 47 47 44 .800
BMI, kg/m2 22.3 ± 5.8 23.3 ± 4.5 23.3 ± 4.0 .016
Duration of nephrologist care, days 117 [5, 923] 715 [281, 1723] 872 [307, 1748] .000
Vascular access, % 46 74 86 .000
Diabetic nephropathy 44 45 39 .404
Systolic BP, mmHg 158 ± 25 154 ± 25 154 ± 25 .070
Diastolic BP, mmHg 82 ± 15 78 ± 14 80 ± 15 .000
CTR, % 55 ± 8 53 ± 6 53 ± 6 .002
Hemoglobin, g/dL 8.6 ± 1.6 8.7 ± 1.5 9.5 ± 1.4 .000
Hemoglobin/dose of ESAa - 0.51 [0.36, 0.73] 0.40 [0.28, 0.72] .000
Albumin, g/dL 3.3 ± 0.6 3.4 ± 0.6 3.5 ± 0.5 .002
Creatinine, mg/dL 8.9 ± 3.4 9.6 ± 3.3 9.6 ± 3.1 .012
eGFR, mL/min/1.732 5.7 ± 3.0 5.1 ± 1.9 4.9 ± 2.0 .000
Total cholesterol, mg/dL 186 ± 64 172 ± 47 162 ± 44 .000
Triglyceride, mg/dL 122 [84, 182] 109 [78, 154] 110 [83, 150] .082
HDL-C, mg/dL 50 ± 19 49 ± 17 47 ± 16 .473
Calcium, mg/dL 7.8 ± 1.1 7.9 ± 1.0 8.0 ± 1.0 .013
Phosphate, mg/dL 6.3 ± 1.8 6.0 ± 1.5 6.3 ± 1.6 .010
Ca x P product 47 ± 16 47 ± 12 49 ± 15 .067
i-PTH, pg/mL 291 [171, 421] 265 [168, 403] 291 [168, 446] .176
CRP, mg/dL 0.10 [0.05, 0.17] 0.10 [0.02, 0.13] 0.14 [0.04, 0.20] .000
glucose, mg/dL 132 ± 55 140 ± 52 138 ± 50 .156
Fe, μg/dL 72 ± 36 67 ± 34 65 ± 38 .167
TIBC, μg/dL 231 ± 56 233 ± 45 236 ± 43 .644
Ferritin, ng/dL 140 [73, 282] 117 [57, 204] 105 [49, 193] .077
Dose of ESA, per month 0 12,000 [12,000, 24,000] 24,000 [12,000, 36,000] .000
ARB/ACE-I, % 56 67 65 .003
Vitamin D, % 21 31 44 .000
AST-120, % 9 22 18 .000
Iron, % 10 21 23 .001
Data are expressed as the mean ± SD, median [interquartile range], or percentage
BMI body mass index, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein, i-PTH intact
parathyroid hormone, CRP c-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin receptor blocker, ACE-I
angiotensin-converting enzyme inhibitor
aHemoglobin was corrected by dose of ESA per 1000units
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CKD patients maintain their Hb near the optimal level
even in a severely uremic state, which is one of the
strongest causes of ESA-resistant anemia.
Assessment of the effects of long-acting ESA on Hb level
The ability to use a higher dosage of epoetin could ex-
plain the beneficial effect of long-acting ESA on Hb.
Based on the instructions for the use of long-acting ESAin the drug package insert, and referring to the recom-
mended dose conversion ratio from darbepoetin or
CERA to epoetin [15, 16], we can theoretically prescribe
an approximately 1.5 times higher monthly estimated
dose of epoetin in the predialytic phase of CKD. In
Japan, max monthly dosage of epoetin-α or -β is
24,000 IU in predialytic phase of CKD patients. For
darbepoetin-α and CERA, max monthly dosages are 240
and 250 μg, respectively. Based on the dose conversion
Table 3 Univariate linear regression analysis for the factors associated with Hb level
Regression coefficient 95 % CI P
Age, years .036 −0.002 .010 .195
Male .047 −0.023 .320 .089
Diabetes .059 .014 .343 .033
BMI .018 −0.024 .012 .524
Duration of nephrologist care .013 .000 .000 .655
Vascular access .151 .320 .674 .000
Diabetic nephropathy .026 −0.112 .039 .339
Systolic BP .014 −0.004 .002 .622
Diastolic BP .048 −0.001 .011 .090
CTR .157 −0.05 −0.022 .000
Albumin .176 .330 .619 .000
Creatinine .162 −0.1 −0.05 .278
eGFR .187 .090 .163 .000
Total cholesterol .11 .001 .005 .000
Triglyceride .074 .000 .003 .013
HDL-C .040 −0.002 .009 .188
Calcium .201 .223 .383 .000
Phosphate .088 −0.134 −0.032 .001
Ca x P product .020 −0.004 .008 .467
i-PTH .049 −0.001 .000 .113
C-reactive protein .002 −1.087 1.016 .948
Glucose .016 −0.001 .002 .585
Fe .068 .000 .005 .021
TIBC .087 .001 .005 .003
Ferritin .074 −0.001 .000 .013
ESAa .031 −.079 .285 .268
Long-acting ESAb .205 0.524 0.967 .000
Dose of ESA, per 1000 units .075 .002 .019 .015
ARB/ACE-I .019 −0.113 .233 .497
Vitamin D .020 −0.12 0.253 .484
AST-120 .017 −0.148 .275 .554
Iron .000 −0.176 .176 .999
BMI body mass index, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein, i-PTH intact
parathyroid hormone, CRP c-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin receptor blocker, ACE-I
angiotensin-converting enzyme inhibitor
aDummy variables was used for usage of any type of ESA (0 for not used, 1 for used)
bDummy variables was used for type of ESA (0 for short-acting ESA, 1 for long-acting ESA)
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CERA, at least one-half dosage of estimated epoetin was
applicable to CKD patients. Indeed, as shown in Table 1,
an estimated dose of epoetin 1.5 times higher was
administered to the patients after 2011 compared
with before 2010. It is thought that the switch from a
short-acting to a long-acting ESA increases the available
estimated dose of epoetin, and consequently, the Hb level
at the initiation of dialysis.Iron status is one of the important parts for the opti-
mal treatment of anemia in ESKD patients. The differ-
ence of iron utilization could play some role more
increasing of Hb level in patients with long-acting ESA
than those of short-acting ESA. Actually, it is reported
that difference of type of ESA [18] or difference of ad-
ministration interval of ESA [19] make a changing of
iron status favorably for treatment of anemia in ESKD
patients. However, any remarkable differences did not
Table 4 Independent association of use and dose of long-acting ESA with Hb level by multiple linear regression analysis
Model Adjustment Regression coefficient 95 % CI P
Model 1a Unadjusted Long-acting ESA 0.204 0.515 1.02 .000
Dose of ESA/1000 units 0.024 −0.007 0.014 .483
Model 2b Age, sex, diabetes, BMI, SBP, vascular access, nephrologists care, CTR Long-acting ESA 0.191 0.427 0.976 .000
Dose of ESA/1000 units −0.019 −0.014 0.008 .613
Model 3c Model 2 + albumin, CRP Long-acting ESA 0.169 0.341 0.912 .000
Dose of ESA/1000 units −0.013 −0.013 0.009 .721
Model 4d Model 2 + TC, TG,HDL-C, Glu Long-acting ESA 0.196 0.41 1.039 .000
Dose of ESA/1000 units −0.023 −0.017 0.01 .588
Model 5e Model 2 + Ca, P, iPTH, vitamin D long-acting ESA 0.186 0.388 0.948 .000
Dose of ESA/1000 units −0.022 −0.015 0.008 .570
Model 6f Model 2 + Fe, TIBC, ferritin, iron tx Long-acting ESA 0.168 0.275 0.848 .000
Dose of ESA/1000 units −0.029 −0.018 0.009 .503
Model 7g Model 2 + ACEI/ARB, AST-120 Long-acting ESA 0.188 0.411 0.962 .000
Dose of ESA/1000 units −0.016 −0.014 0.009 .683
Model 8h All Long-acting ESA 0.155 0.176 0.858 .003
Dose of ESA/1000 units −0.029 −0.019 0.01 .555
aUnadjusted
bAdjusted for age, sex, diabetes nephropathy, BMI, SBP, vascular access, duration of nephrologists care, and CTR
cAdjusted for variables in model 2 plus albumin and CRP
dAdjusted for variables in model 2 plus total cholesterol, triglyceride, high lipoprotein cholesterol, and glucose
eAdjusted for variables in model 2 plus calcium, phosphate, and intact-PTH
fAdjusted for variables in model 2 plus Fe, TIBC, ferritin, and usage of iron medication
gAdjusted for variables in model 2 plus usage of angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, and AST-120
hAdjusted for all variables from model 2 to 7
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and short-acting ESA in the marker of iron status such
as iron, ferritin, TSAT, and usage of iron agents. There-
fore, it is not likely that the status and utilization of iron
play some role for increasing Hb level in long-acting
ESA in this study.
Another possibility is that, independent of dose, the
potential direct effect of a long-acting ESA could play a
role in the elevation of Hb level at the initiation of dialy-
sis. On multiple regression analysis, use of long-acting
ESA was more closely associated with Hb level than its
estimated dose from the conversion ratio in our study.
Several studies have suggested that the conversion ratio
from epoetin to darbepoetin-α of 1:350 in the clinicalTable 5 Independent association of categorical Hb level with
using of long-acting ESAa
Hemoglobin, g/dL Odds ratio 95 % CI p
<7.0 0.673 0.302–1.502 .334
7.0–7.9 0.858 0.476–1.548 .611
8.0–8.9 1
9.0–9.9 2.218 1.349–3.646 .002
10.0–10.9 2.844 1.652–4.896 .000
≥11.0 3.102 1.596–6.031 .001
aAdjusted by age, sex, BMI, diabetes, albumin, eGFR, and CRPsetting is higher than the fundamental conversion ratio
from the molecular structure of 1:200 [15, 20]. This
might mean that darbepoetin-α has a potentially more
powerful effect on increasing the Hb than we expected.
Further study is needed to prove this issue.
Many clinical factors are thought to affect the Hb level
at the initiation of dialysis. Residual renal function is
thought to be the biggest contributor to Hb levels in
CKD patients. It is well known that a positive relationship
exists between endogenous erythropoietin concentration
and the serum eGFR [21] in CKD patients. The present
study was conducted by using a combined database from
nine hospitals. The question arises of whether the policy
and indication for starting dialysis are not standardized,
but rather, are at each physician’s discretion. This could
make a difference in the timing for starting dialysis, and,
consequently, influence the Hb concentration at the initi-
ation of dialysis. Therefore, in order to minimize this bias,
multivariate regression analysis was performed to adjust
for confounding variables, including renal function. After
adjusting by serum creatinine level or eGFR, the positive
association of long-acting ESA with Hb level remained
statistically significant. Also, after simultaneously adjusting
for other factors, as seen in Tables 4 and 5, the use of
long-acting ESA was well-associated with Hb concentra-
tion. These findings imply that long-acting ESA plays a
Asakawa et al. Renal Replacement Therapy  (2016) 2:12 Page 9 of 10beneficial role in maintaining a higher Hb concentration
than short-acting ESA. The reason is probably the higher
estimated epoetin dose or other potential effect. We
would like to emphasize that excluding the patients with
suspicion of low responsiveness to ESA could lead an
anticipating results.
Limitations
A major limitation of the present study was the study
design. A cross-sectional study design cannot be used to
prove clear any causal effect of ESA on Hb level. The
data available to us concerning ESA covered only the
dosage in the month immediately before the initiation of
dialysis. No information about the duration of ESA treat-
ment existed in our database. To minimize such bias, we
attempted to perform multivariate analysis including the
factors “Duration of nephrologist care before initiation
of dialysis” and “vascular access.” These two factors may
be markers of CKD patients’ adaptation to dialysis, the
patients’ compliance with their nephrologists’ care plans,
and the degree of patient education received by the pa-
tients. After adjusting for these two markers, the associ-
ation of long-acting ESA with Hb remained statistically
significant. These results suggest that long-acting ESA
could increase the Hb level in the advanced stages of
CKD even in a relatively short duration of treatment.
Another limitation of the present study is that the target
Hb level may be not consistent among doctors or hospi-
tals. However, we do have confirmed with all the mem-
bers of J-START that management of anemia in the
predialytic phase was performed essentially based on the
Japanese guidelines published in 2004 and 2008 [8, 22].
Especially, from 2008, we changed the management of
anemia to a protocol based on the Japanese guidelines
[8]. The target Hb levels for non-dialyzed patients were
almost the same in both guidelines from 11 to 12 g/dL.
Third, we have a look at the trend for decreasing of per-
centage of diabetic nephropathy, which is different from
those of western countries. This difference could make
an advantage to our finding. However, even including
diabetic nephropathy in multivariate analysis, our main
finding that the positive association of long-acting ESA
use with Hb was observed remained significant. There-
fore, we believe that the bias has no big influence to our
results. Fourth, about 50 % of ESKD patients showed
CRP level over 0.3 mg/dL and were excluded from our
study. As we described in the method area, blood sample
data in this study was collected just before the first HD
session. Advanced uremic state can lead to non-infected
chronic inflamed state. Also, uremic state would be the
cause of immune dysfunction consequently susceptible
to infectious disease. Based on these assessments, it is
reasonable to find that about 50 % of ESKD patients at
the initiation of dialysis showed CRP level over 0.3 mg/dLon the blood sampling just before the first HD session.
Actually, DOPPS study [23] demonstrated that median
CRP level of 1392 Japanese stable chronic hemodialysis
patients is 0.1 mg/dL with interquartile range from 0.05 to
0.31 mg/dL. This means that about 25 % of patients
showed CRP level over 0.3 mg/dL even in stable dialysis
patients.
Conclusions
The use of long-acting ESAs such as darbepoetin-α and
CERA elevates the Hb level in the advanced stages of
CKD. This effect might be mainly due to the ability to
use a higher estimated dose of epoetin. However, the
cross-sectional design of the present study does not offer
proof of the causal effect of long-acting ESA on Hb at
the initiation of dialysis. It is therefore essential to begin
a longitudinal study to prove this potential beneficial ef-
fect of ameliorating anemia in CKD patients.
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